Display options
Cite
Yang J, Liu Y, He A, et al. Hsa-miR-429 promotes bladder cancer cell proliferation via inhibiting CDKN2B. Oncotarget. 2017;8(40):68721-68729doi: 10.18632/oncotarget.19878.
Yang, J., Liu, Y., He, A., Liu, Y., Wu, J., Liao, X., Lv, Z., Wang, F., & Mei, H. (2017). Hsa-miR-429 promotes bladder cancer cell proliferation via inhibiting CDKN2B. Oncotarget, 8(40), 68721-68729. https://doi.org/10.18632/oncotarget.19878
Yang, Jiangeng, et al. "Hsa-miR-429 promotes bladder cancer cell proliferation via inhibiting CDKN2B." Oncotarget vol. 8,40 (2017): 68721-68729. doi: https://doi.org/10.18632/oncotarget.19878
Yang J, Liu Y, He A, Liu Y, Wu J, Liao X, Lv Z, Wang F, Mei H. Hsa-miR-429 promotes bladder cancer cell proliferation via inhibiting CDKN2B. Oncotarget. 2017 Aug 03;8(40):68721-68729. doi: 10.18632/oncotarget.19878. eCollection 2017 Sep 15. PMID: 28978151; PMCID: PMC5620291.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Aug 03;8(40):68721-68729. doi: 10.18632/oncotarget.19878. eCollection 2017 Sep 15.

Hsa-miR-429 promotes bladder cancer cell proliferation via inhibiting CDKN2B.

Oncotarget

Jiangeng Yang, Yuchen Liu, Anbang He, Yuhan Liu, Jianting Wu, Xinhui Liao, Zhaojie Lv, Feng Wang, Hongbing Mei

Affiliations

  1. Department of Urology, Shenzhen Second People's Hospital, Clinical Institute of Guangzhou Medical University, Shenzhen 518039, Guangdong Province, China.
  2. Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University Shenzhen, Guangdong Province, China.
  3. Anhui Medical University, Anhui, China.

PMID: 28978151 PMCID: PMC5620291 DOI: 10.18632/oncotarget.19878

Abstract

BACKGROUND AND OBJECTIVES: Hsa-miR-429 is increased in bladder cancer. Its roles in bladder cancer are poorly understood.

METHODS: The expression levels of hsa-miR-429 and cyclin-dependent kinase inhibitor 2B (CDKN2B) were determined using Real-Time qPCR in a total of 50 patients with bladder cancer. Bladder cancer T24 and 5637 cells were transfected CDKN2B siRNA or hsa-miR-429 mimic. CDKN2B expression levels after transfection were detected by Real-Time qPCR and Western blot assay respectively. Binding sites between hsa-miR-429 and 3'-untranslated region of CDKN2B were confirmed by Dual luciferase reporter assay. Cell proliferation was evaluated using MTT and EdU assays. Cell apoptosis was determined using ELISA assay.

RESULTS: Higher hsa-miR-429 expression levels were associated with higher tumor grade and stage. All patients with low hsa-miR-429 expression survived 5 years, while with high hsa-miR-429 expression, only 58% survived. Hsa-miR-429 and CDKN2B were inversely expressed in bladder cancer. Hsa-miR-429 mimic decreased the expression of CDKN2B at both mRNA and protein levels. The binding site was confirmed between hsa-miR-429 and 3'-untranslated region of CDKN2B. Up-regulation of hsa-miR-429 or down-regulation of CDKN2B promoted cell growth and decreased apoptosis.

CONCLUSIONS: Our data suggest a mechanism for hsa-miR-429 to play oncogenic roles via inhibiting CDKN2B.

Keywords: cyclin-dependent kinase inhibitor 2B; microRNA; urothelial carcinoma

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare that they have no conflicts of interest with this work.

References

  1. Biochem Biophys Res Commun. 2013 Aug 23;438(2):439-44 - PubMed
  2. Nature. 2010 Aug 12;466(7308):835-40 - PubMed
  3. Cancer Genet Cytogenet. 2009 Nov;195(1):59-65 - PubMed
  4. FEBS Lett. 2011 Jan 3;585(1):187-92 - PubMed
  5. Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4034-9 - PubMed
  6. Int J Mol Med. 2008 Sep;22(3):271-5 - PubMed
  7. Med Sci Monit. 2016 Sep 22;22:3352-3361 - PubMed
  8. Cancer Discov. 2015 Jul;5(7):723-9 - PubMed
  9. Urology. 2013 Jan;81(1):209.e1-7 - PubMed
  10. Oncotarget. 2015 Dec 8;6(39):42258-75 - PubMed
  11. Nat Rev Genet. 2009 Oct;10(10):704-14 - PubMed
  12. Med Sci Monit. 2017 Feb 18;23 :881-888 - PubMed
  13. CA Cancer J Clin. 2013 Jan;63(1):11-30 - PubMed
  14. Biotechniques. 2008 Apr;44(5):619-26 - PubMed
  15. Med Sci Monit. 2017 Feb 24;23 :1001-1008 - PubMed
  16. Biomed Pharmacother. 2016 May;80:311-21 - PubMed
  17. Biochem Biophys Res Commun. 2012 Oct 12;427(1):165-70 - PubMed
  18. Anticancer Res. 2015 Mar;35(3):1401-10 - PubMed
  19. Nat Methods. 2016 Nov;13(11):938-944 - PubMed
  20. Oncotarget. 2016 May 3;7(18):26593-603 - PubMed
  21. FEBS Lett. 2013 Nov 29;587(23):3875-82 - PubMed
  22. PLoS One. 2011 Mar 28;6(3):e18286 - PubMed
  23. Tumour Biol. 2016 Nov;37(11):14653-14658 - PubMed
  24. Anal Quant Cytol Histol. 2009 Feb;31(1):5-16 - PubMed

Publication Types